Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV study of Gla-300 basal-bolus regimen in hospitalized type 2 diabetes patients and basal insulin intensification after discharge
2015-004715-20Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, single-arm trial of insulin glargine U300 in type 2 diabetes mellitus (T2DM), sponsored by Sanofi. Primary endpoint: Mean change in HbA1c from discharge to month 6. Started Jan 2016; status: completed.
02
Drugs
insulin glargine U300
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-004715-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004715-20.